Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18973168 | 1.00 | KDM4E (0.31) | KDM4EALPL | |
| SCHEMBL17489316 | 0.92 | POLB (0.36) | KDM4E | |
| SCHEMBL19657863 | 0.89 | AURKA (0.34) | — | |
| SCHEMBL17476448 | 0.89 | AURKA (0.34) | — | |
| SCHEMBL22166375 | 0.89 | POLB (0.33) | KDM4E | |
| SCHEMBL20433740 | 0.89 | KDM4E (0.37) | KDM4E | |
| SCHEMBL14090164 | 0.89 | HTR2A (0.33) | KDM4E | |
| SCHEMBL13422023 | 0.88 | KDM4E (0.37) | KDM4E | |
| SCHEMBL5926038 | 0.88 | KDM4E (0.37) | KDM4E | |
| SCHEMBL12347417 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260205-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-14 | — | — | US | disclosed |
| US-9688694-B2 | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260205-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | GABRA1, GABRA2, GABRA3 | KDM4E 2095/4885ALPL 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.